INTRODUCTION {#S0001}
============

Breast cancer, first described as early as 3000 B.C. by Edwin Smith Papyrus of Egypt, comprises 23% of all female malignancies (excluding non--melanomatous skin cancer) \[[@CIT0001], [@CIT0002]\]. In 2008, the number of deaths from breast cancer totaled 460,000 patients; it is a global concern accounting for 14% of all cancer deaths in females \[[@CIT0003]\]. It is the most common invasive cancer in women with an incidence that ranges between 19.3 per 100,000 in Eastern Africa to 89.7 per 100,000 in Western Europe \[[@CIT0004], [@CIT0005]\]. The mortality in breast cancer patients is attributed to metastatic disease \[[@CIT0003], [@CIT0006]\]. It is known to metastasize to numerous organs including lymph nodes, lung, bone, liver, skin, kidneys, brain, adrenal, thyroid, and heart \[[@CIT0003], [@CIT0006], [@CIT0007], [@CIT0008]\]. Breast cancer metastasizing to the urinary bladder has only been reported sporadically totaling 41 cases in the English medical literature \[[@CIT0003], [@CIT0009]--[@CIT0013]\]. Bladder metastasis from breast cancer as the only organ involved is very rare, with only eight cases reported worldwide \[[@CIT0003], [@CIT0011], [@CIT0012], [@CIT0014]\]. We herein present a patient who presented with bladder metastasis from breast cancer with the bladder being the only organ involved.

CASE REPORT {#S0002}
===========

A 64--year--old female patient, a non--smoker known to have hypertension, diabetes mellitus, dyslipidemia, supraventricular tachycardia, and osteoporosis was diagnosed in 2005 with left breast intraductal carcinoma. She underwent a modified radical mastectomy with lymph node dissection. Ten out of 23 nodes were positive; she was staged as T2 (4 cm) N3 M0 disease. Receptors were positive for estrogen and progesterone, but negative for Her2. The patient was treated with eight cycles of chemotherapy, adriamycin, cytoxan,and taxol and 25 sessions of radiation therapy (total dose of 50 grays), and completed a 5--year treatment with an aromatase inhibitor. She had no evidence of disease until March 2010, when she presented to our clinic with recurrent urinary tract infections and urinary incontinence that failed to resolve with antibiotics alone. Her symptoms progressed and she developed severe disabling dysuria and suprapubic pain. She also reported intermittent bouts of bilateral flank pain radiating to her groin area.

Workup included a computed tomography (CT) scan of her abdomen and pelvis, which showed diffuse thickening of the urinary bladder wall with surrounding fat streaking of the pelvis and retroperitoneum ([Figure 1](#F0001){ref-type="fig"}). There was evidence of mild right hydroureteronephrosis with no evidence of obstructing urinary tract calculi ([Figure 1](#F0001){ref-type="fig"}). Cystoscopy showed inflammatory changes and suspicious bladder wall thickening in multiple areas. Transuretheral resection of bladder tumor (TURBT) for suspicious lesions was performed.

![Axial CT scan of the abdomen and pelvis without contrast. A, B. Diffuse thickening of the urinary bladder wall (arrows) with surrounding fat streaking of the pelvis. A pocket of gas is noted C, D. Mild right hydroureteronephrosis (arrowheads).](CEJU-66-00259-g001){#F0001}

Pathology showed an unremarkable bladder mucosa, but a submucosal nest of carcinoma cells was found. The tumor was CK7 and CK20 negative, consistent with primary breast carcinoma. The cells were plasmacytoid with marked nuclear pleomorphism, frequent mitotic figures and multiple foci suggestive of lymphovascular invasion were present. The tumor cells were positive for estrogen receptor and E--cadherin; they were negative for progesterone receptors. This is consistent with breast ductal carcinoma ([Figure 2](#F0002){ref-type="fig"}).

![A. H&E sections of the urinary bladder biopsy revealing a dense submucosal infiltrate (mag. 40x). B. The cells are cohesive, plasmacytoid with an abundant eosinophilic cytoplasm and eccentric nucleus (mag. 400x). The cells demonstrate positive immunostaining with anti--estrogen receptor (ER) antibody (C, mag. 400x) and anti--cytokeratin--7 (CK--7) antibody (D, mag. 200x).](CEJU-66-00259-g002){#F0002}

Chest CT scan and bone scan were performed as part of the full work--up and failed to show any evidence of other distant metastasis. The patient was started on adriamycin, cyclophosphamide, and zometta. Follow--up re--TURBT was not performed. One week after receiving the first cycle of chemotherapy, the patient developed hematuria and clot retention. Several attempts of irrigation failed so the decision was made to perform cystoscopy in order to fulgurate all bleeders. The cystoscopy identified a large clot in the bladder, which was removed and all bleeding areas were fulgurated. No gross evidence of residual tumor or recurrence was identified. Symptoms were relieved. Chemotherapy was continued and was complicated by neutropenia. The patient was clinically stable and tolerated the treatment. However, a few days after the third chemotherapy cycle she developed severe dyspnea and was found to have pneumonia that progressed to septic shock. The patient passed away from cardiorespiratory arrest one year after the diagnosis of the bladder metastasis.

DISCUSSION {#S0003}
==========

Until 2012, 41 cases of bladder metastasis from breast cancer have been reported and they were mostly associated with systemic dissemination and multiple organ involvement. Only eight cases of solitary bladder metastasis from primary breast cancer have been documented and our case represents the ninth in the English medical literature \[[@CIT0003], [@CIT0011], [@CIT0012], [@CIT0014]\] ([Table I](#T0001){ref-type="table"}, in bold). Most cases were diagnosed by cystoscopy and biopsy. Macroscopically, bladder metastasis may appear as a mass, irregular lesion, mucosal nodularity, abnormally thickened bladder wall, or plaque with telangiectasias. Any area of the urinary bladder can be involved. In our case, cystoscopy was performed based on the suspicious CT scan findings, and it revealed an abnormal bladder wall thickening and inflammation, which were both subsequently biopsied. Multiple sites of the urinary bladder were involved by carcinoma on pathology.

       Reference/ year            GU symptoms                                                             Finding on cystoscopy                                         Primary tumor to mets   Site in bladder                      Bladder as only mets   Other organ involvement                   Bladder mets to death   Chemotherapy used before bladder mets                                              Breast/ Bladder ER/PR   Breast tumor subtype   Treatment for bladder metastasis
  ---- -------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------- ----------------------- ------------------------------------ ---------------------- ----------------------------------------- ----------------------- ---------------------------------------------------------------------------------- ----------------------- ---------------------- ----------------------------------
  1    Ganem and Batal. 1956      Gross Hematuria                                                         Large tumor                                                   10 yrs                  Left Lateral wall                    No                     Bone, skin                                \>12 mo                 Stilbesterol                                                                       NR                      NR                     NR
  2    Perez--Mesa et al. 1965    Gross hematuria, frequency, dribling                                    Ulcerating tumor mass                                         2 yrs                   Posterior wall                       No                     Bone, LN                                  NR                      Fluoxymesterone                                                                    NR                      NR                     NR
  3    Perez--Mesa et al. 1965    Gross hematuria, urinary frequency                                      Defined tumor mass                                            18 yrs                  Infiltrated Tumor                    No                     LN, bone, omentum                         12 mo                   5--Fluorouracil                                                                    NR                      NR                     NR
  4    Grabstald et al. 1969      Hydronephrosis                                                          NR                                                            NR                      NR                                   NR                     NR                                        NR                      NR                                                                                 NR                      NR                     NR
  5    Pontes & Oldford 1970      Hematuria, low back pain                                                Tumor mass                                                    1 yr                    Right Ureteral orifice               No                     Widespread                                2 mo                    Stilbesterol                                                                       NR                      NR                     Chemotherapy
  6    Pontes & Oldford 1971      Back Pain                                                               Cauliflower tumor mass                                        4 yrs                   Right lateral wall                   No                     LN, retroperitoneum                       1 mo                    Estrogen                                                                           NR                      Poorly anaplastic      Radiation
  7    Schapira et al. 1980       Gross hematuria, Suprapubic pain                                        Telangiectasia and whitish plaque                             5 yrs                   Left lateral wall                    No                     NR                                        NR                      NR                                                                                 NR                      NR                     Radiation
  8    Haid et al. 1980           Gross hematuria                                                         Irregular sessile tumor                                       5.5 yrs                 NR                                   No                     Bone, Brain, meninges, Liver              1 mo                    Hydrocortisone                                                                     NR                      NR                     NR
  9    Haid et al. 1981           Frequency, nocturia, urge incontinence                                  Mucosal nodularities, restricted capacity                     2.5 yrs                 Adherent vaginal wall                No                     Skin, pelvis                              1 yr                    DES                                                                                NR                      NR                     NR
  10   Haid et al. 1982           Microscopic hematuria, abnormal cytology                                Not performed                                                 2.5 yrs                 NR                                   No                     Bone, meninges, lung, liver, peritoneum   1                       Tamoxifen                                                                          NR                      NR                     Chemotherapy
  11   Mairy et al. 1982          None                                                                    NR                                                            9 mo                    ExtraLuminal on partial cystectomy   No                     Skin, bone                                Alive \>14 mo           NR                                                                                 NR                      NR                     NR
  12   Haid et al. 1983           Left adnexal mass                                                       Walnut--size Tumor                                            3 yrs                   Left ureteral orifice                No                     LN, Pelvis                                Alive \>7 mo            Methotrexate, 5--FU, prednisone, L--phenylalanine                                  NR                      NR                     Radiation+ Chemotherapy
  13   Mairy et al. 1983          Frequency, dysuria, incontinence, polyuria                              Swollen mass                                                  Same time               Left lateral wall                    No                     Bone, endometrium, skin                   Alive \>13 mo           NR                                                                                 NR                      NR                     NR
  14   Silverstein et al. 1987    Frequency, urgency, nocturia, abdominal pain                            Smooth, hard raised immobile lesion                           14 yrs                  Right lateral wall                   Yes                    None                                      2 yr                    No                                                                                 NR +/NR                 NR                     NR
  15   Silverstein et al. 1988    Gross hematuria, dysuria                                                Extensive nodularity                                          7 mo                    Right lateral wall/trigone           No                     Brain, Bone                               5 yr                    Cyclophosphamide, prednisone,5 FU                                                  --/-- NR                NR                     NR
  16   Rigatti et al. 1991        Renal colic, microscopic hematuria                                      Exophitic mass                                                5 yrs                   Right perimeatal                     No                     LN                                        NR                      Cyclophosphamide, methotrxate,5 FU                                                 NR                      NR                     NR
  17   Rigatti et al. 1992        Irritative symptoms, incontinence                                       Small elevated reddened area                                  13 yrs                  Lateral wall                         No                     LN, lung                                  NR                      Tamoxifen, medroxyprogesterone                                                     NR                      NR                     NR
  18   Berger et al. 1992         Microscopic hematuria                                                   Abnormal lesion                                               NR                      Right Lateral/posterior wall         Yes                    None                                      NR                      5--FU, cyclophosphamide, MitomycinC, doxorubicin, vinblastine, megestrol acetate   --/-- NR                IDC                    NR
  19   Berger et al. 1993         Urinary retention, vaginal mass,gross hematuria                         Abnormal lesion                                               6 yrs                   NR                                   No                     Supraclavicular node, bone, brain         \<1 yr                  Tamoxifen, methotrexate, 5--FU, cyclophosphamide                                   NR                      NR                     Radiation + Chemotherapy
  20   Berger et al. 1994         Gross hematuria                                                         Not performed                                                 5.7 yrs                 NR                                   No                     Retroperitoneum, liver, SB/LB             \<1 yr                  cyclophosphamide, tamoxifen, methotrexate, prednisone, vincristine, 5--FU          +/-- NR                 ILC                    Chemotherapy
  21   Williams et al. 1992       Frequency, nocturia, hydronephrosis                                     Large tumor mass                                              30 yrs                  Trigone                              NR                     NR                                        NR                      NR                                                                                 NR                      NR                     NR
  22   Schneidaue et al. 1995     Flank pain, gross hematuria, dysuria                                    Diffuse bullous edema                                         4 yrs                   Base, posterolateral wall            No                     Meninges                                  NR                      Cyclophosphamide, methotrexate, 5--FU                                              NR                      NR                     NR
  23   Lucas et al. 1996          Macroscopic hematuria                                                   Large hypervascular                                           2.8 yrs                 NR                                   No                     Skin, lung, brain                         \<1 yr                  Vindesine, mitomycin, tamoxifen                                                    NR                      NR                     Radiation
  24   Elias et al. 1999          Urgency                                                                 Few small polyps                                              5 yrs                   Left lateral wall                    Yes                    None                                      Alive \>1 yr            Tamoxifen                                                                          +/+ --/ +               IDC                    Hormonal therapy
  25   Poulakis et al. 2001       Frequency, urgency, nocturia                                            Multiple invasive tumor                                       5 yrs                   NR                                   Yes                    Bladder recurrence                        Alive \>5 yrs           Tamoxifen                                                                          +/+ +/ +                NR                     NR
  26   Feldman et al. 2002        Gross hematuria                                                         Irregularities                                                10 yrs                  Left lateral wall                    No                     Ovary                                     Alive \>9 mo            Cyclophosphamide, doxorubicin, 5--Fu, Tamoxifen                                    --/-- +/NR              ILC                    Radiation
  27   Choudhary et al. 2003      Mixed Urinary incontinence                                              Atrophic hemorrhagic trigone                                  18 yrs                  Trigone                              Yes                    None                                      Alive \>8 mo            NR                                                                                 NR +/NR                 NR                     NR
  28   Soon et al. 2004           Mixed Urinary incontinence                                              Poorly compliant bladder                                      NR                      Right side                           Yes                    None                                      NR                      NR                                                                                 NR                      ILC                    Hormonal therapy
  29   Auprich et al. 2004        Gross hematuria, urge incontinence                                      Two large tumors                                              2 yrs                   NR                                   No                     Bone                                      NR                      NR                                                                                 NR                      NR                     NR
  30   Lawrentschuk et al. 2005   Nocturia                                                                Abnormal lesion                                               NR                      NR                                   NR                     NR                                        NR                      NR                                                                                 +/-- +/--               ILC                    NR
  31   Gatti et al. 2005          NR                                                                      Ulcerated mass                                                5 yrs                   NR                                   NR                     NR                                        NR                      NR                                                                                 NR                      IDC + ILC              Chemotherapy
  32   Lawrentschuk et al. 2006   Groin pain, hydronephrosis                                              Abnormal lesion                                               NR                      NR                                   NR                     NR                                        NR                      NR                                                                                 +/+ +/--                iLC                    NR
  33   Zagha et al. 2006          NR                                                                      Ulcerated mass                                                8 yrs                   NR                                   NR                     NR                                        NR                      NR                                                                                 NR                      NR                     Surgery + hormone
  34   Ryan et al. 2006           Urinary incontinence                                                    Rigid infiltrating mass                                       NR                      Posterior wall                       No                     NR                                        NR                      NR                                                                                 Nr +/--                 NR                     NR
  35   Foster et al. 2006         Back Pain, malaise                                                      Excessive nodular tumor                                       NR                      Trigone                              No                     NR                                        NR                      NR                                                                                 +/+ +/ +                NR                     NR
  36   Lin et al 2007             NR                                                                      Irregular mucosa and nodular lesions                          3 yrs                   NR                                   NR                     NR                                        NR                      NR                                                                                 NR                      NR                     Chemotherapy
  37   E. Vulcano et al. 2010     Urinary frequency and nocturia                                          Irregular lesion of the bladder dome                          6 yrs                   Dome                                 Yes                    None                                      2 yrs                   NR                                                                                 NR/+ NR/--              ILC                    Chemotherapy + hormonal therapy
  38   Kamlesh et al. 2011        Fever with chills, bilateral pedal edema, oliguria and hydronephrosis   Thick irregular bladder wall with no definitive mass lesion   Same time               Diffuse                              NR                     None                                      6 mo                    NR                                                                                 NR/+ NR/--              ILC                    Chemotherapy
  39   Xiao et al. 2012           Difficult urination, hydronephrosis                                     Fixed bladder neck obscuring orifice                          NR                      Trigone, bladder neck                Yes                    Neck, liver, lung                         0.5 mo                  NR                                                                                 NR/+ NR/ +              ILC                    NR
  40   Xiao et al. 2012           Difficult urination, hematuria                                          Mass obscuring ureteral orifice                               NR                      Trigone, posterior wall              No                     None                                      1 mo                    NR                                                                                 NR/+ NR/ +              ILC                    NR
  41   Xiao et al. 2012           NR                                                                      Nodular lesion                                                NR                      Bladder neck, periurethra            NR                     NR                                        NR                      NR                                                                                 NR/+ NR/ +              Inflammatory           NR
  42   Abou Ghaida et al. 2013    Frequency, dysuria, incontinence, hydronephrosis                        Lesions                                                       5 yrs                   Diffuse                              Yes                    None                                      1 yr                    Adriamycin, Cytoxan, Taxol                                                         +/+ +/--                IDC                    Chemotherapy

Abbreviations: GU -- genitourinary, NR -- not reported, mets -- metastasis, LN -- lymph node, SB -- small bowels, LB -- large bowels, ILC-- invasive lobular carcinoma, IDC -- invasive ductal carcinoma, ER -- estrogene receptors, PR -- progesterone receptors

The breast primary tumor subtype was invasive intraductal carcinoma while in the previously published reports, the most common histology of the breast primary was invasive lobular (10 out of the 15 cases where the breast cancer subtype was determined).

Bates and Baithun reported 4.5% incidence of secondary bladder metastasis among all bladder cancer \[[@CIT0009], [@CIT0015]\], with secondary metastasis to the bladder from breast cancer being approximately 3% \[[@CIT0016], [@CIT0017]\]. When autopsy and pathology are used as mainstay for diagnosis, the incidence ranges from 0% to 7% \[[@CIT0018]\]. Bladder metastasis from previously diagnosed breast cancer is reported in the literature to vary from 2% to 14% \[[@CIT0003]\]. The most common primary tumors metastasizing to the bladder are: stomach, lung, skin/melanoma, and breast \[[@CIT0019]\].

Symptomatic secondary bladder involvement from breast cancer is detected at late stages. It is only when the mucosa is involved by the disease will symptoms become clinically detectable. Metastasis involves the outer layer of bladder wall and progresses inward towards the mucosa \[[@CIT0018]\]. Since mucosal involvement is the last stage of metastatic invasiveness into the bladder, the prognosis is very poor with a mean survival of two to three years, although a 5--year survival of two patients out of the 41 was reported in the literature \[[@CIT0014], [@CIT0020]\]. As a consequence, early stages of breast cancer metastasizing to the bladder are unapparent clinically, and detection of the disease remains a diagnostic challenge.

The most common findings in patients with secondary bladder metastasis are lower urinary tract symptoms (LUTS), flank or abdominal pain, hydronephrosis, and the painless hematuria that is in many cases the most common initial symptom (microscopic being more frequent than gross) \[[@CIT0019]\]. Hematuria as a sign of bladder involvement following primary breast cancer is considered sensitive, but not specific for tumor metastasis. Gross hematuria with a history of breast cancer needs to be thoroughly investigated, keeping in mind the side effects of cyclophosphamide as treatment of the primary breast cancer, regardless of time or duration of treatment. However, our patient did not present with hematuria. Instead, she complained from recurrent urinary tract infections and urinary incontinence. Suprapubic and bilateral flank pain was later the major disabling symptom that warranted the investigation through CT scan imaging.

Ca 15--3 is one method to follow up breast cancer recurrence or metastasis \[[@CIT0021]\], but strong evidence are lacking on its clinical usefulness. The positron emission tomography (PET) scan has been showed to have increasing usage after suspecting bladder involvement in a breast cancer patient; however, its cost effectiveness is yet to be determined \[[@CIT0022]\].

Breast metastasis to the bladder has been shown to have a worse prognosis than metastasis to bone \[[@CIT0016]\]. The time interval between primary tumor diagnosis and detection of metastasis is highly variable between 0 month and 30 years with an average of 6.2 years ([Table 1](#T0001){ref-type="table"}). Bladder metastases in our patient were identified five years after the initial diagnosis of primary breast carcinoma. Conduction of the proper investigations prevented the delay in the diagnosis of the metastatic disease. The patient survived one year from the time she first presented with urinary symptoms, and there was no evidence that her death was related to the bladder metastasis.

Only 8% of all breast cancer is lobular carcinoma \[[@CIT0019]\], however, it is the most common type of breast cancer type involving the bladder (33% of secondary bladder metastasis) followed by ductal carcinoma, which accounts for the majority of primary breast cancer (66%) and metastasizes mostly to the lung parenchyma \[[@CIT0019]\]. One hypothesis is that lobular carcinoma is of the serosal type, which gives it a predilection to spread to the gastrointestinal and gynecological systems \[[@CIT0023]\]. It is part of the seeding soil hypothesis: the interaction of tumor with specific host factors in the metastasized organ \[[@CIT0018]\]. The strongest predictor is lymph node involvement in the primary disease. Another culprit is concomitant steroid therapy, which is thought to be due to exacerbation of the immunosuppressive effect \[[@CIT0019]\].

Estrogen, progesterone, and Her2 receptors are the three main receptors studied in breast cancer. Bladder metastasis from primary breast cancer was also subject to receptor studies \[[@CIT0024]\]. Discrepancy between receptors is not uncommon between the primary and the secondary tumor (reported between 30 and 39%) \[[@CIT0024]\]. Bladder metastases from our case were positive for estrogen receptors, which was also true for the patient\'s known primary cancer of the breast. However, progesterone receptors were only present in the malignant breast cells and not the secondary bladder metastasis. One hypothesis is that the polyclonicity of breast tumor cells is affected by treatment modalities (hormonal therapy may select some and suppress others), which manifests itself later in case of bladder metastasis \[[@CIT0017]\]. It has been shown that if receptors convert from positive in the breast to negative in the bladder, it is associated with decrease survival \[[@CIT0017], [@CIT0024]\]. Even with receptor--negative secondary bladder metastasis, a trial of anti--receptor therapy has been used with promising results in controlling disease \[[@CIT0024]\].

Reported cases of bladder metastasis were managed through surgery, chemotherapy, radiotherapy, hormonal therapy, or a combination of those. In our patient, chemotherapy was initiated after the TURBT and continued for three cycles. Neutropenia and the resultant complications went against the completion of the therapeutic plan.

CONCLUSIONS {#S0004}
===========

We report a rare case of breast cancer with solitary urinary bladder metastasis that was diagnosed several years after the initial presentation. Secondary malignancies of the bladder are difficult to distinguish from non--transitional cell primary bladder cancer. A high level of suspicion and extensive investigation are warranted if a known primary cancer already exists. We emphasize the need to be more aware of the possible metastatic nature of every urinary symptom that shows in a breast cancer patient.
